Baker Hughes Company filed a Form 8-K on September 9, 2026, disclosing that Chairman, President and Chief Executive Officer Lorenzo Simonelli would present at the Barclays 2026 CEO Energy-Power Conference in New York that same day, including updated fiscal-year 2026 financial guidance incorporating the …
Oil prices rose Wednesday, withBrent Crudefutures crossing the $100 threshold for the first time since July, as escalating tensions between the US and Iran fueled concerns over further disruptions to Middle East energy supplies. Brent futures were last trading more than 2.5% higher at …
Postal Realty Trust, Inc. filed a Form 8-K on September 9, 2026, disclosing that it closed on the acquisition of a 72-property portfolio leased to the United States Postal Service for approximately $27.75 million, effective September 4, 2026.
The Chemours Company filed a Form 8-K with the SEC on September 9, 2026, disclosing that it had posted an investor presentation to its website for use in upcoming meetings with investors, analysts, and other interested parties.
Sysco Corporation filed a Form 8-K with the SEC on September 9, 2026, disclosing that the company reaffirmed its fiscal 2027 guidance, announced a $500 million multi-year AI powered efficiency improvement program, and raised certain mid-term financial algorithm targets.
Independence Realty Trust, Inc. filed a current report on September 9, 2026, disclosing that on September 8, 2026, it entered into an Agreement and Plan of Merger with Centerspace, a North Dakota real estate investment trust, under which each Centerspace share would be converted …
Albertsons Companies, Inc. filed a Form 8-K on September 9, 2026, disclosing the appointment of Margaret Whitman to its Board of Directors as Executive Chair, effective September 8, 2026.
Twenty One Capital, Inc. filed a Form 8-K on September 9, 2026, disclosing the appointment of David J. Goldschmidt to its Board of Directors and Audit Committee, effective September 8, 2026.
D-Wave Quantum Inc. filed a Form 8-K/A (Amendment No. 1) on September 9, 2026, reporting the execution of a Securities Issuance Agreement with the U.S. Department of Commerce and the issuance of common stock in connection with an Other Transaction Agreement providing for an …
Kura Oncology, Inc. filed a Form 8-K on September 9, 2026, disclosing the formation of a wholly owned subsidiary, Caspian Therapeutics, Inc., and the completion of a $50.0 million Series A preferred stock financing for that subsidiary on September 8, 2026.